Across TCGA pan-cancer cohorts, TIGIT Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TIGIT data layer compared with 23 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher TIGIT Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TIGIT expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
COAD and UCEC are the cancer types where TIGIT Mutation most reproducibly stratifies survival.